Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
This study assessed the effect of nanoparticles (NMCAB) on the biodistribution and viral clearance profiles of current CAB LAP formulations.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks or every 8 weeks was as effective as daily three-drug oral therapy at maintaining HIV-1 viral suppression through 96 weeks and was well accepted and tolerated.
Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient’s perspective.
The aim of this review is to summarize the biological bases, the available information on completed and ongoing clinical trials and the potential development of long-acting regimens for the treatment and prevention of HIV infection.
HIV Capsid Lenacapavir Review Treatment & Prevention, PK, Mechanism, Resistance
Ongoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.
HIV Capsid Lenacapavir Review Treatment & Prevention, PK, Mechanism, Resistance Read More »
Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date
Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for prevention and treatment regimens that could overcome challenges of improving adherence, toxicity, and dosing convenience.
Cabotegravir as Pre-Exposure Prophylaxis for HIV Prevention
HPTN/IMPAACT Network Meeting 2016 Presentation
Cabotegravir as Pre-Exposure Prophylaxis for HIV Prevention Read More »
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
This study assesses cabotegravir plus rilpivirine, as a two-drug oral antiretroviral regimen, for the maintenance of viral suppression in antiretroviral-naive HIV-1-infected individuals.
Formulation and pharmacology of long-acting cabotegravir
The pharmacologic profile of long-acting cabotegravir supports its continued development for both treatment and prevention of HIV-1 infection.
Formulation and pharmacology of long-acting cabotegravir Read More »
Cabotegravir long-acting for HIV-1 prevention
PrEP, after approval of Truvada, continues to evolve to address adherence limitations of daily dosing. As a long-acting injectable antiretroviral drug, cabotegravir long-acting permits quarterly dosing and demonstrated high efficacy in macaque models supporting dose selection and clinical development. Clinical studies have confirmed dose selection in phase 2a trials with cabotegravir long-acting to ultimately lead
Cabotegravir long-acting for HIV-1 prevention Read More »